Abstract library

319 results for "WHO 2010 classification".
#2976 Incidence of Appendiceal NEN and Adherence to Pathological Classification Rules and Treatment Guidelines: Results of the Population Based Cancer Registry in Belgium
Introduction: Classification of appendiceal neuroendocrine neoplasms (aNEN) changed significantly over the years and treatment algorithm remains a matter of debate.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Karen Geboes
#2857 Clinical Epidemiology Study of Rectal Neuroendocrine Neoplasms in China: A National Multicenter 10-Year Retrospective Study
Introduction: Representative data on the rectal neuroendocrine neoplasms in Chinese patients is rare.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: professor Fan Jinhu
Authors: Jinhu F, Yihebali C, Huan Y, Su Z, ...
#2741 Histologic Grading of Neuroendocrine Tumors and Its Relationship of Survival
Introduction: Current classification divides NENs into neuroendocrine tumors (NETs) and neuroendocrine carcinoma (NEC). NENs at different anatomic sites require site-specific applications for the classification.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: student Sofija Vilisova
#2939 Prognostic Evaluation for Gastroenteropancreatic NEC: AJCC or ENETS Staging Classification or Others?
Introduction: For poorly-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), American Joint Committee on Cancer (AJCC) recommends to use a classification different from that for well-differentiated neuroendocrine tumor. However, this is not adopted by European Neuroendocrine Tumor Society (ENETS) staging classification.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Professor Jie Chen
Authors: Zhang Y, Chen L, Lin Z, Zhang T, ...
#106 Gastroenteropancreatic neuroendocrine tumors: single institution clinicopathological study
Introduction: Neuroendocrine cells are widely distributed throughout the body, and neoplasms from these dispersed cells can arise at many sites. They are distinguished into two broad categories: 1) Tumors identified as small cell lung carcinomas with biology and natural history of a high-grade malignancy and characteristics of small cell undifferentiated or anaplastic appearance by light microscopy. The WHO categorizes these tumors as poorly-differentiated neuroendocrine carcinomas; 2) Well-defined neuroendocrine tumors (NETs) with variable, but most lyindolent biologic behavior and characteristic well-differentiated histologic features. The majority arise in the gastrointestinal tract and collectively they are referred as gastroenteropancreatic neuroendocrine tumors (GEP/NETs). They include carcinoid tumors, pancreatic islet cell tumors (gastrinoma, insulinoma, glucagonoma, VIPoma, somatostatinoma), paragangliomas, pheochromocytomas, and medullary thyroid carcinomas. The WHO classifies the GEP/NETs as well-differentiated NETs (carcinoid tumors) if they are noninvasive and have benign behavior or uncertain malignant potential. In contrast, GEP/NETs with characteristics of low-grade malignancy with invasion of the muscularis propria or beyond, or metastases, are characterized as well-differentiated neuroendocrine carcinomas (malignant carcinoids). Pancreatic islet cell tumors, whether functioning or not, are classified as well-differentiated NETs or well-differentiated neuroendocrine carcinomas, due to the (depending on) histologic characteristics. The WHO classification for gastroenteropancreatic NETs based on stage (ie size and presence of metastases) and grade (mitotic rate, perineural and lymphovascular invasion, Ki-67 proliferative index) categorizes them as well-differentiated NETs, e.g., carcinoid tumors, or as well-differentiated neuroendocrine carcinomas.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Michael M. Vaslamatzis
#214 Comparison of the AJCC and ENETS Staging Classifications for Neuroendocrine Tumors of the Pancreas
Introduction: The AJCC Cancer Staging Manual (7th edition, 2010) has introduced a novel TNM staging classification for pancreatic NETs. This classification has not yet been validated.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
Authors: Strosberg J, Cheema A, Weber J, Kvols L, ...
#249 Management of Insulinomas: Perioperative and Long-term Outcomes Following Enucleations and Pancreatic Resections in 198 Patients
Introduction: Enucleation represents the procedure of choice for the treatment of insulinomas. Considering the site and the number of lesions, however, formal pancreatic resection may be necessary.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Stefano Crippa
#326 Long-term Survival and Quality of Life in Patients with Ileum NET: A Single Center Experience
Introduction: Neuroendocrine tumors of the small bowel can be differentiated in terms of progression, survival time and health-related quality of life from endothelial tumors.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Anne Reincke
Authors: Reincke A, Zahn S, Hornung H, Jauch K W, ...
#338 Pancreatic Endocrine Tumors: TNM staging and WHO Grading Relation with Prognosis
Introduction: Pancreatic endocrine tumors (PETs) are heterogeneous, rare neoplasms (large experience is unlikely). Prognostic stratification based on TNM staging and WHO grading is still under debate.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dra. Raquel G. Martins
#418 Chromogranin A (CgA) in the Diagnosis and Monitoring of Patients with Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NET): A Single-Institution Experience
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP NET) are heterogeneous neoplasms with different malignancy. Plasma chromogranin A (CgA) may play an important role in predicting outcome.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Sara Massironi
Keywords: CgA, GEP-NET